Clinical Policy: Homocysteine Testing
Reference Number: CP.MP.121
Last Review Date: 05/20

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Homocysteine is a nonproteinogenic amino acid that is generated during the conversion of methionine to cysteine. Mutations of the enzymes within the biochemical pathways that regulate homeostatic homocysteine levels are associated with risk factors for various diseases, including venous thromboembolism. Supplementation of folic acid, vitamin B6, and vitamin B12 are known to modulate homocysteine levels, given the interplay between the folate cycle and metabolism. This policy describes the medical necessity requirements for testing levels of homocysteine.

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation® that homocysteine testing is medically necessary for homocystinuria caused by cystathionine beta-synthase deficiency.

II. It is the policy of health plans affiliated with Centene Corporation that homocysteine testing is considered investigational for the following indications:
   a. Cardiovascular risk testing;
   b. Borderline vitamin B12 deficiency;
   c. Idiopathic (unprovoked) venous thromboembolism, recurrent venous thromboembolism, thrombosis occurring at < 45 years of age, or thrombosis at an unusual site;
   d. For the testing of all other conditions.

Background
Homocysteine is a naturally occurring intermediary amino acid that is generated during the conversion of methionine to cysteine. While homoeostatic plasma levels of homocysteine typically range at low micro molar concentrations, epistatic mutations and other aberrant modifications of the metabolic pathways modulate homocysteine levels. The metabolic pathway of homocysteine consists of upstream remethylation pathways and a downstream transsulfuration pathway. Notably, mutations in cystathionine-β-synthase, a key enzyme of the transsulfuration pathway, are associated with excess levels of homocysteine and premature thrombotic events. Furthermore, a common mutation at a single nucleotide (677C→T) in the gene encoding 5,10-methenetetrahydrolate reductase, an enzyme in the folate cycle whose byproducts are necessary cofactors in the metabolism of homocysteine, affects homoeostatic levels of homocysteine. This mutation predisposes the individual to low folate plasma levels, and consequently a status of hyperhomocysteine.

Changes in the plasma homocysteine levels can result from alterations in folate or vitamin B6 or vitamin B12. A meta-analysis of 25 randomized clinical trials demonstrated that daily supplementation of ≥ 0.8 mg folic acid is sufficient to achieve the maximal reduction in plasma homocysteine levels. Moreover, basal levels of homocysteine range between 5-15 μmol/L,
while moderate hyperhomocysteine concentrations are 15-30 μmol/L, intermediate levels are 30-100 μmol/L and severe hyperhomocysteine concentrations are >100 μmol/L.\textsuperscript{7}

Hyperhomocysteine was identified as an independent risk factor for ischemic heart disease and vascular disease.\textsuperscript{3,4} Initial reports hypothesized that heterozygosity of cystathionine-β-synthase contributed to the accumulation of homocysteine, and these reports were corroborated by later meta-analyses.\textsuperscript{3,4} However, this rationale has not been corroborated, as two randomized controlled trials, the Heart Outcomes Prevention Evaluation 2 (Hope-2) and the Norwegian Vitamin (NORVIT) trials simultaneously demonstrated no effect from lowering homocysteine levels, by way of folic acid or vitamin B6 supplementation, on cardiovascular outcomes.\textsuperscript{5,6}

A 2017 Cochrane review of homocysteine-lowering interventions for preventing cardiovascular events concluded that B-vitamin supplements lowered homocysteine but did not reduce risk of myocardial infarction or reduce death rates in patients at risk of, or living with cardiovascular disease.\textsuperscript{11} Compared with placebo, lowered homocysteine resulting from B-vitamin supplementation combined with antihypertensive medications produced uncertain benefit in preventing stroke- approximately 143 people would need to be treated for 5.4 years to prevent 1 stroke.\textsuperscript{11}

Hyperhomocysteine has been suggested as a risk factor for venous thromboembolic disease. Ray et al. performed a meta-analysis of 9 case control studies measuring fasting plasma homocysteine, as well as 5 studies measured after methionine loading. All 9 studies demonstrated a similar trend in the levels and the associated risk for venous thromboembolism; following methionine loading, the trend increased toward the risk of venous thromboembolism.\textsuperscript{9,10} However, hyperhomocysteinemia has been associated with venous thromboembolic disease in some but not all studies. Additional research has concluded that associations between “mild” hyperhomocysteinemia and VTE may have been due to confounding by body mass index and cigarette smoking.\textsuperscript{17}

Homocysteine testing has also been used to diagnose vitamin B12 deficiency, in combination with methylmalonic acid (MMA). Homocysteine levels are a sensitive and specific measure of established vitamin B12 deficiency, but its role is unclear in the evaluation of borderline B12 deficiency, where it would be most useful.\textsuperscript{20} Furthermore, MMA testing without concurrent homocysteine testing has been recommended in the assessment of low-normal vitamin B12 levels.\textsuperscript{21}

High levels of serum homocysteine have been proposed as a risk factor for dementia, and several studies have evaluated the role of B-vitamin supplementation in lowering homocysteine and thus improving cognitive function, or preventing cognitive decline. A meta-analysis by Clarke et al. determined that B-vitamin supplementation significantly reduced homocysteine levels, but did not have a clinically significant effect on global cognitive function or on cognitive aging.\textsuperscript{12} In contrast, a 2018 International Consensus Statement argues for the presence of a causal relationship between homocysteine levels and cognitive decline, and for screening for hyperhomocysteine and treatment with B vitamins in patients presenting to memory clinics.\textsuperscript{13} However, the consensus body notes that 76% of the participants in the trials in the largest meta-analysis on the topic did not include baseline measures of cognitive function, and thus couldn’t
adequately compare the intervention group to the placebo group. Furthermore, they point to the lack of an established homocysteine threshold for intervention, which reduces the clinical relevance of the measure.

**Coding Implications**
This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>83090</td>
<td>Homocysteine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E72.10</td>
<td>Disorders of sulfur-bearing amino-acid metabolism, unspecified</td>
</tr>
<tr>
<td>E72.11</td>
<td>Homocystinuria</td>
</tr>
<tr>
<td>E72.19</td>
<td>Other disorders of sulphur-bearing amino-acid metabolism</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Review Description</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed</td>
<td>07/16</td>
<td>08/16</td>
</tr>
<tr>
<td>References reviewed and updated</td>
<td>07/17</td>
<td>08/17</td>
</tr>
<tr>
<td>Background updated. References reviewed and updated.</td>
<td>05/18</td>
<td>05/18</td>
</tr>
<tr>
<td>Background updated. References reviewed and updated. Specialist review</td>
<td>04/19</td>
<td>05/19</td>
</tr>
<tr>
<td>References reviewed and updated. Revised I.A from “Borderline vitamin B12 deficiency” to “Borderline low or inconclusive Vitamin B12 deficiency, or discordant with the clinical picture.”</td>
<td>03/20</td>
<td>04/20</td>
</tr>
<tr>
<td>Changed borderline B12 deficiency and idiopathic VTE/thromboembolism indications from medically necessary to investigational. Added supporting background information and references. Removed from the list of ICD-10 codes supporting coverage criteria: D51.0-D51.9, E53.8, I26.01-I26.99, I81, I82.0-I82.91, Z86.711, Z86.718.</td>
<td>05/20</td>
<td>05/20</td>
</tr>
</tbody>
</table>
CLINICAL POLICY
Homocysteine Testing

References
Clinical Policy
Homocysteine Testing


Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.
This clinical policy is the property of the Health Plan. Unauthorized copying, use, and
distribution of this clinical policy or any information contained herein are strictly prohibited.
Providers, members and their representatives are bound to the terms and conditions expressed
herein through the terms of their contracts. Where no such contract exists, providers, members
and their representatives agree to be bound by such terms and conditions by providing services to
members and/or submitting claims for payment for such services.

**Note: For Medicaid members,** when state Medicaid coverage provisions conflict with the
coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence.
Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical
policy.

**Note: For Medicare members,** to ensure consistency with the Medicare National Coverage
Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs,
and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by
Centene Corporation and are protected by United States copyright law and international
copyright law. No part of this publication may be reproduced, copied, modified, distributed,
displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise
published without the prior written permission of Centene Corporation. You may not alter or
remove any trademark, copyright or other notice contained herein. Centene® and Centene
Corporation® are registered trademarks exclusively owned by Centene Corporation.